THE MERCK VETERINARY MANUAL
Print Topic

Sections

Chapters

Tumors of the Immune System

-
-

The cells of the immune system may become neoplastic. This may result in the production of tumor cells that are nonfunctional and hence lead to immunodeficiencies. Alternatively, they may be functional, and some cancerous B cells may produce large quantities of immunoglobulins.

Tumor cells escape from the immune attack by relying on both immunosuppression and tumor cell modification. The demonstration that even bulky, invasive tumors can undergo complete remission under appropriate stimulation (eg, IL-2) has shown that it is indeed possible to treat some cancers successfully by immune manipulation.

Lymphomas are common tumors in dogs and cats. The normal adaptive response requires a burst of rapid proliferation of lymphocytes. On occasion, however, this proliferation may be uncontrolled, and lymphoid neoplasms result. Because lymphocytes are present in all organs, lymphoid tumor development can occur in any organ. Lymphomas can be multicentric, mediastinal, GI, renal, nervous, or leukemic. Less commonly, they occur in the eyes, skin, or nose. To determine the stage of the disease, CBC, serum chemistry profiles, abdominal ultrasound, abdominal radiographs, and bone marrow analyses are useful. Immunofluorescent staining and immunophenotyping can be performed in dogs and cats to characterize lymphomas. They may be either T cell or B cell in origin.

Most cases of canine lymphosarcoma, Marek's disease, calf leukosis, and feline leukemia are of T-cell origin, as are thymomas. Many T-cell lymphomas are associated with a simultaneous immunosuppression manifest by a predisposition to recurrent infections.

Adult bovine and ovine leukosis, alimentary feline leukemia, and avian leukosis are usually of B-cell origin. Under some circumstances, neoplastic B cells may develop into plasma cells. Plasma-cell tumors are known as myelomas. Because neoplastic plasma cells can secrete immunoglobulins, they give rise to gammopathies (see below).

Last full review/revision September 2013 by Ian Tizard, BVMS, PhD, DACVM

Copyright     © 2009-2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.    Privacy    Terms of Use    Permissions